Human papillomavirus Associated Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Human papillomavirus Associated Cancer Pipeline Report
• Over 50+ Human papillomavirus Associated Cancer companies are evaluating 50+ Human papillomavirus Associated Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Human papillomavirus Associated Cancer market would significantly increase market revenue.
• The leading Human papillomavirus Associated Cancer Companies working in the market include PDS Biotech, pHion Therapeutics Ltd., NexImmune, Precigen, Vaccitech, Nykode Therapeutics ASA, MedImmune LLC, Avalia Immunotherapies, Repertoire Immune Medicines, Kinopharma, Immunovaccine Inc., Inovio Pharmaceuticals, Voltron Therapeutics, Inc., SQZ Biotech, Kovina Therapeutics, Rubius Therapeutics, Transgene, BioNTech, 2A Pharma ApS, Genexine, Inc., Viracta Therapeutics, Inc., Myrio Therapeutics, Vault Pharma, GeoVax, IOVANCE Biotherapeutics, Inc., Advaxis, Astex Pharmaceuticals, Biond Biologics Ltd, BlueSky Immunotherapies, CHAIN Biotech, eTheRNA immunotherapies, ISA Pharmaceuticals, and others.
• Promising Human papillomavirus Associated Cancer Pipeline Therapies in the various stages of development include PDS0101, PTX_V1, PTX_V2, NEXI-003, PRGN-2009, VTP1100, VB10.16, MEDI0457, AVA1156, DPX-E7, VGX-3100, SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV, HB-200, RTX-321, TG4001, BNT113, GX-188E, VPI-241, Axalimogene, ASTX660, delNS/E6E7, ISA101b, and others are under development in different phases of clinical trials.
• July 2023: Toragen Inc. announced a study of Phase 1 clinical trials for TGN-S11 and Pembrolizumab. This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.

Request a sample and discover the recent advances in Human papillomavirus Associated Cancer Treatment Drugs @ Human papillomavirus Associated Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Human papillomavirus Associated Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Human papillomavirus Associated Cancer NDA approvals (if any), and product development activities comprising the technology, Human papillomavirus Associated Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Human papillomavirus Associated Cancer Overview
Human papillomavirus (HPV) infection is linked with several cancers such as cancer cervix, vagina, head and neck, anal, and carcinomas. Although there is a proven association of HPV with these cancers, questions regarding HPV testing, vaccination, and treatment of HPV-related cancers continue to remain unanswered. The present article provides an overview of the HPV-associated cancers.

Find out more about Human papillomavirus Associated Cancer Therapeutics Assessment @ Human papillomavirus Associated Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Human papillomavirus Associated Cancer Emerging Drugs Profile

STP909: Sirnaomics Inc
STP909 comprises siRNA targeting human papillomavirus (HPV) sequences formulated with our PNP delivery platform for intravenous and topical administration. Company developing STP909 as a prophylactic vaccine for prevention of cervical cancer and other disease caused by HPV.

RTX-321: Rubius Therapeutics
RTX-321 is an allogeneic, off-the-shelf aAPC therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.

BVAC-C: Cellid Co Ltd
BVAC-C uses HPV type 16/18's carcinogen gene, E6/E7's recombination gene as antigen to apply on cervical cancer, head and neck cancer, anal cancer, and sex organ cancer caused by HPV infection. CeliVax-based pipeline, BVAC-C, completed phase-I clinical trial to check safety and it is currently undergoing phase-II clinical trial to check effectiveness.

GX-188E: Genexine Inc
GX-188E is a DNA therapeutic vaccine fused with encoding both E6 and E7 antigens as well as the extracellular domain of Flt3L to target and activate dendritic cells. GX-188E has ability to induce a tumor-specific CD8+ immune response and functional activity to eliminate target cells against high-grade cervical intra-epithelial neoplasms (CIN3, carcinoma in-situ). A phase 1b/2 clinical trial for the cervical cancer patients to evaluate safety, tolerability and efficacy is currently ongoing.

ITI-2000: Immunomic Therapeutics Inc
ITI-2000 provides an UNITE platform address for HPV+ cancers. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product. ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers.

Human papillomavirus Associated Cancer Therapeutics Assessment
There are approx. 50+ key Human papillomavirus Associated Cancer companies which are developing the therapies for Human papillomavirus (HPV) Associated Cancer. The companies which have their Human papillomavirus (HPV) Associated Cancer drug candidates in the most advanced stage, i.e. Phase III include Advaxis.

DelveInsight's Human papillomavirus Associated Cancer pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Human papillomavirus (HPV) Associated Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Human papillomavirus Associated Cancer Products have been categorized under various Molecule types such as
• Small molecule
• Gene Therapy
• Cell Therapy
• Immunotherapy

Learn more about the emerging Human papillomavirus Associated Cancer Pipeline Therapies @ Human papillomavirus Associated Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Human papillomavirus Associated Cancer Pipeline
• Coverage- Global
• Human papillomavirus Associated Cancer Companies- PDS Biotech, pHion Therapeutics Ltd., NexImmune, Precigen, Vaccitech, Nykode Therapeutics ASA, MedImmune LLC, Avalia Immunotherapies, Repertoire Immune Medicines, Kinopharma, Immunovaccine Inc., Inovio Pharmaceuticals, Voltron Therapeutics, Inc., SQZ Biotech, Kovina Therapeutics, Rubius Therapeutics, Transgene, BioNTech, 2A Pharma ApS, Genexine, Inc., Viracta Therapeutics, Inc., Myrio Therapeutics, Vault Pharma, GeoVax, IOVANCE Biotherapeutics, Inc., Advaxis, Astex Pharmaceuticals, Biond Biologics Ltd, BlueSky Immunotherapies, CHAIN Biotech, eTheRNA immunotherapies, ISA Pharmaceuticals, and others.
• Human papillomavirus Associated Cancer Pipeline Therapies- PDS0101, PTX_V1, PTX_V2, NEXI-003, PRGN-2009, VTP1100, VB10.16, MEDI0457, AVA1156, DPX-E7, VGX-3100, SQZ-PBMC-HPV, SQZ-AAC-HPV, SQZ-eAPC-HPV, HB-200, RTX-321, TG4001, BNT113, GX-188E, VPI-241, Axalimogene, ASTX660, delNS/E6E7, ISA101b, and others.
• Human papillomavirus Associated Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human papillomavirus Associated Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Human papillomavirus Associated Cancer Treatment, Visit @ Human papillomavirus Associated Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Human papillomavirus (HPV) Associated Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human papillomavirus (HPV) Associated Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac: Advaxis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PRGN-2009: Precigen PII
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. HB-200: Hookipa Pharma Inc
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Human papillomavirus (HPV) Associated Cancer Key Companies
24. Human papillomavirus (HPV) Associated Cancer Key Products
25. Human papillomavirus (HPV) Associated Cancer - Unmet Needs
26. Human papillomavirus (HPV) Associated Cancer - Market Drivers and Barriers
27. Human papillomavirus (HPV) Associated Cancer - Future Perspectives and Conclusion
28. Human papillomavirus (HPV) Associated Cancer Analyst Views
29. Human papillomavirus (HPV) Associated Cancer Key Companies
30. Appendix

For further information on the Human papillomavirus Associated Cancer Pipeline therapeutics, reach out to Human papillomavirus Associated Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/human-papillomavirus-hpv-associated-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.